Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?
The side-effect profile of cyclophosphamide is well-known and most clinicians only prescribe it in the most severe disease. This review compares cyclophosphamide to mycophenolate mofetil for induction and maintenance therapy for severe lupus nephritis. Using the available evidence, the authors conclude that mycophenolate mofetil is a viable alternative for therapy, although cyclophosphamide may have a role under specific circumstances.
- Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study
- Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial